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Screening of the small molecule library of Meinox enables the identification of
anticancer compounds in pathologically distinct cancers
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Abstract: Small molecules are widely used for the modulation of the molecular basis of diseases. This makes them the perfect tool for
discovering and developing new therapeutics. In this work, we have established a library of small molecules in house and characterized
its molecular and druglike properties. We have shown that most small molecules have molecular weights less than 450. They have
pharmaceutically relevant cLogP, cLogS, and druglikeness value distributions. In addition, Meinox’s small molecule library contained
small molecules with polar surface areas that are less than 60 square angstroms, suggesting their potent ability to cross the bloodbrain barrier. Meinox’s small molecule library was also tested in vitro for pathologically distinct forms of cancer, including pancreatic
adenocarcinoma PANC1, breast carcinoma MCF7, and lymphoblastic carcinoma RS4-11 cell lines. Analysis of this library at a dose of 1
μM allowed the discovery of potent, specific or broadly active anticancer compounds against pathologically distinct cancers. This study
shows that in vitro analysis of different cancers or other phenotypic assays with Meinox small molecule library may generate novel and
potent bioassay-specific compounds.
Key words: Screening, small molecules, Meinox small molecule library, cytotoxicity

1. Introduction
Small molecule libraries accelerate the exploration of
chemical leads that act as a starting point for novel
therapeutics (Coussens et al., 2017; Bayram et al., 2018;
Demirel et al., 2018; Beksac et al., 2020; Özenver and
Efferth, 2020). With this approach, biologically and
physiologically relevant assays can be rapidly tested,
with the complex chemical space of thousands of small
molecules. The discovery techniques for small molecules
are commonly defined in phenotypic cell-based tests and
biochemical target-based tests (Mohammadi et al., 2020).
These include but not limited to target-based approaches,
mechanism-modulated assays, phenotypic assays,
combination assays, patient-derived cells for personalized
therapeutic development, ex vivo tumor models such as
organoids, spheroids, and tumor fragments (reviewed in
(Coussens et al., 2017)).
A commonly used paradigm for the treatment of
various human malignancies is combination drug therapy
(Boztas et al., 2013; Bakhshaliyev et al., 2020). Additive
and synergistic drug formulations in cancer care can turn
weakly successful monotherapy treatments into regimens

that deliver vigorous antitumor action (Daglioglu,
2017; Karpuz et al., 2018; Kacı et al., 2020). This can be
explained in part by the interdependence of receptors
that are important for the growth and survival of cancer
(Gökbulut et al., 2015). However, because of the intricate
molecular machinery that underlies tumor growth and
progression, recognition of multiple interdependencies is
difficult (Kaymaz et al., 2015). Further experiments are also
required to eradicate these pathways of interdependence
and drug resistance (Kara et al., 2021). This also requires
development of new small molecule library that is suitable
for high-throughput testing ( Zaka et al., 2018; Kanan et
al., 2020).
For the drug development, the exploitation of new
chemical entities (NCEs) in various bioassays, and
combinatorial studies, and to provide a novel, local and
easy to access screening tool, Meinox has developed a novel
library of small molecules. Meinox small molecule library
includes over a thousand distinct and pharmacological
molecules, and it is likely to be expanding to tens of
thousands compounds soon with NCEs.
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In this work, a novel library of small molecules has been
developed and its molecular and druglike properties have
been characterized. Around a thousand small molecules
from the Meinox repository were tested for their effect
on cancer viability at a dosage of 1 μM for three different
cancers. The goal of these compounds was to reduce the
viability of MCF7 breast carcinoma, PANC1 pancreatic
adenocarcinoma and RS4-11 lymphoblastic leukemia cell
lines by at least 50%. For each cancer type, we have aimed
to define specific hits with anticancer action. This study
suggests that in vitro screening with the small molecule
library of Meinox may generate novel and effective
compounds related to the bioassays or cancer used.
2. Methods
2.1. Small molecule library preparations
The Meinox small molecule library chemicals are dissolved
dimethyl sulfoxide (DMSO) as 10 mM main stocks. They
have been diluted with PBS to obtain 100X working stocks
before use in cell culture studies. List of compounds is
provided on the http://www.meinoxtech.com/meinoxsmall-molecule-library.html.
2.2. Computational analysis of Meinox library of small
molecules
Meinox small molecule library includes over thousand
druglike compounds in house, which is established with the
support of medical chemists in Turkey, and antiparasitic/
pandemic small molecule projects. Small molecules
were characterized for their general molecular and lead/
druglikeness properties. We analyzed their molecular
weight, cLogP, cLogS, Polar surface area, fragmentbased druglikeness value, and toxicity risk assessment
for mutagenicity, tumorogenicity, irritating effects, and
reproductive effects using DataWarrior (López-López et
al., 2019). Histograms are prepared using online Shodor
Histogram platform.
2.3. Cell culture and viability assays
Breast carcinoma cell line MCF7 (ATCC HTB-22),
pancreatic adenocarcinoma cell line PANC1 (ATCC
CRL-1469), and lymphoblastic leukemia cell line RS4-11
(ATCC CRL-1873) were cultured and passaged according
to ATCC’s recommendations. Briefly, 10 × 103 MCF7 and
7.5 × 103 PANC cells were seeded into 96-well plates/well
the day before small molecule treatments. A total of 200 ×
103 RS4-11 cells/well were passaged in the growth medium
and treated with 1 μM of small molecules from Meinox
library on the same day. DMSO (0.5%) treatments were
used as a control. After four days of treatments, cancer
viability was assessed by CellTiter (Promega) according
to manufacturer’s protocol as we have done previously
(Boztas et al., 2013; Turan et al., 2020).
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2.4. Structural clustering and statistical analysis
Using Cactus server (https://cactus.nci.nih.gov/translate/),
we have generated 3D SDF files of the ligands. Using
ChemBioServer 2.0 (https://chembioserver.vi-seem.eu/
index.php), hit clustering was performed. The distance
form of Soergel (Tanimoto coefficient) and average linkage
clustering were chosen. Statistical analysis was carried out
by comparing chosen hits to the entire library of small
molecules using the Student’s t-test. p values less than 0.05
were deemed significant.
3. Results
3.1. Analysis of molecular and lead/druglike properties
of Meinox small molecule library
We established a library of small molecules with the
support of medical chemists and molecular biologist who
provided small molecules that are biologically relevant and
subject to further characterization for drug discovery and
development. First version of the Meinox small molecule
library included 1000 small molecules. We sought to
determine the molecular and druglike properties of small
molecules by analyzing molecular weight, hydrophilicity
(cLogP), aqueous solubility (cLogS), polar surface area
(PSA), druglikeness value based on fragment analysis,
and toxicity risk assessment for potential mutagenicity,
tumorigenicity, irritating effects, and reproductive
effects by computation tools. This is followed by in vitro
analysis of compounds in breast carcinoma, pancreatic
adenocarcinoma, and lymphoblastic leukemia cell lines
(Figure 1).
Our analysis showed that majority (over 70%)
of Meinox small molecule library compounds have
molecular weight of 450 (Figure 2A), which is a good
indication for druglikeness given that over 80% of traded
pharmaceuticals have a molecular weight below 450.
cLogP measurements provided potential hydrophilicity,
absorption or permeation of studied compounds. We have
found that majority of Meinox small molecule library
demonstrated cLogP values smaller than 5.0, similar to
pool of traded small molecule drugs in the market (Figure
2B). In addition, aqueous solubility of compounds were
in the range of over –4 for cLogS values showing that
majority of compounds are likely to have some degree of
aqueous solubility (Figure 2C). Moreover, we determined
the distribution of compounds based on their potent cell
permeability and ability to penetrate the blood-brain
barrier by analysis of polar surface area. Given PSA values
in the drugs that are likely to act on the central nervous
system have below 60 square angstroms, we considered
compounds in the Meinox library to likely to have ability
act in this difficult to targeted region of the body. We have
found that there is a large number of compounds that fits
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Figure 1. Meinox small molecule library was tested and validated in pancreatic
adenocarcinoma (PANC1), breast carcinoma (MCF7), and lymphoblastic
leukemia (RS4-11) in 1 μM final concentrations for cancer viability.
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Figure 2. Analysis of molecular and lead/druglike properties of Meinox small molecule library. Distribution of A)
molecular weight, B) cLogP (associated with hydrophilicity, absorption or permeation), C) cLogS (associated with
aqueous solubility), D) polar surface area (associated with cell permeability and penetration into blood-brain barrier),
and E) druglikeness.

into PSA criteria (Figure 2D). Furthermore, druglikeness
based on the assessment of fragment-based approach in
Meinox small molecule library showed that about 70% of
the compounds have a positive druglikeness value (i.e. >0),
which is in correlation with known drugs (Figure 2E).

3.2. Meinox small molecule library allows identification
of compounds specifically could block breast, pancreas
and leukemia growth
Meinox small molecule library compounds are maintained
in DMSO as 10 mM stocks and diluted to 100X working
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stocks before use in cell culture experiments. Up to
963 compounds were tested in vitro in this study. The
PANC1 pancreatic adenocarcinoma cell line, MCF7
breast carcinoma cell line, and the RS4-11 lymphoblastic
leukemia cell line were used to determine potent anticancer
compound in the Meinox small molecule library. Cancer
cells were seeded into 96-well plates and treated with 1 μM
of small molecules from the Meinox library. Then, cancer
viability was assessed after four days of treatments.
Treatment of Meinox small molecules with PANC1
cells at 1 μM final dose revealed twenty-one compounds
that decrease cell viability at least 50% (Figures 3 and
S1). With the PANC1 cell viability assay, we obtained
an overall viability of 97.2 ± 17.2% with Meinox small
molecules. Mx00300, Mx00710, Mx00737, and Mx00794
demonstrated the most robust cancer cell viability
reduction in PANC1 pancreatic adenocarcinoma cell line.
Treatment of MCF7 cells with Meinox small molecules
(800 compounds) at 1 μM final dose showed five
compounds that decrease cell viability more than 50%
(Figures 4 and S2). We achieved an overall average of
95.0 ± 7.3% viability with MCF7 cells and Meinox small
molecule treatments. Treatment with Mx00201 at 1 μM
final dose resulted in about 80% reduction in cell viability
in MCF7 breast carcinoma cell line.
The treatment of Meinox small molecules (800
compounds) in RS4-11 cells at 1 μM final dose showed

twenty compounds that minimized cell viability by at least
50% (Figures 5 and S3). With the RS4-11 cell viability
assay, we achieved an average viability of 89.5 ± 17.9%
with the small molecules of Meinox. Mx00394, Mx00595,
Mx00737 and Mx00794 showed the most robust decline
in the viability of RS4-11 pancreatic adenocarcinoma cells.
3.3. Analysis of common anticancer compounds from
Meinox small molecule library demonstrates potential
druglike compounds
We wondered if the identified anticancer hits are common
or unique against three distinct cancer types studies
(Figures 6A and 6B). We have found that only five
compounds had common and broad anticancer activity
against breast, pancreas and blood cancer cell lines
studied. These compounds included Mx00691, Mx00710,
Mx00737, Mx00771 and Mx00794. Intriguingly, pancreatic
adenocarcinoma PANC1 and lymphoblastic leukemia
RS4-11 cell lines shared seven additional common
anticancer compounds effective at 1 μM dose. MCF7 and
PANC1 shared two compounds (Mx00201 and Mx00581)
with anticancer properties that do not affect RS4-11 cell
viability at 1 μM dose. Mx00420 compound only reduced
MCF7 cell viability at 1 μM dose, but not PANC1 or RS411 cell lines. Mx00300, Mx00666 and Mx 00458 were
anticancer hits that were only observed in PANC1 cell
viability assays. Besides, RS4-11 had over 19 unique hits

Meinox Small Molecule Library in PANC1 Pancreatic Adenocarcinoma
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Figure 3. Analysis of cell viability posttreatment of PANC1 pancreatic adenocarcinoma cell line with the Meinox small molecule library.

636

MAMMADOVA et al. / Turk J Biol

Meinox Small Molecule Library in MCF7 Breast Carcinoma
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Figure 4. Analysis of cell viability posttreatment of MCF7 breast carcinoma cell line with the Meinox small molecule library.
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Meinox Small Molecule Library in RS4-11 Lymphoblastic Leukemia
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Figure 5. Analysis of cell viability posttreatment of in RS4-11 lymphoblastic leukemia cell line with the Meinox small molecule library.
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Figure 6. Analysis of small molecules in cell viability in the Meinox small molecule library. A) Distribution of common and cancer
type specific small molecules identified with at least 40% reduction in cell viability in MCF7, PANC1 or RS4-11 cancers. B) Percent
viabilities of common thirteen small molecules.

from Meinox small molecule library that lowered cell
viability at least 50%. Furthermore, when we compared
average cell viability of whole small molecule library with
selected hits in each cancer types, we have found significant
difference (p < 10–16 and smaller) (Figure 7).
Common hits identified from this study demonstrated
structural similarities between compounds (Figure 8A).
Analysis of common 14 hits (double or triple hits) by
Tanimoto clustering for MCF7, PANC1 or RS4-11 showed
that they could be classified into four groups (Figure 8B). In
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addition, we determined druglikeness properties (Table).
We found that 10 of 13 hits had below 450 MW. A total of
11 of 13 hits demonstrated cLogP < 5. A total of 7 of 13 hits
had cLogS value bigger than –4. A total of 2 hits had PSA
of below 60. A total of 7 of 13 hits had druglikeness value
>0 indicating their potent drug potential. Furthermore, we
computationally determined potent toxicity risks namely
mutagenicity, tumorigenicity, irritant or reproductive
effects of hits. Majority of hits had no almost none toxicity
risks.
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Figure 7. Analysis of average cell viability of whole library and
common hits. We have calculated cell viability of whole small
molecule library treatments and compared to selected hits for
each cancer. *** indicates at least p <10–16.

In short, we have established a library of small molecules
with potentially and biologically active new chemical
entities. Analysis of this library at 1 μM dose allowed
discovery of potent, unique or broadly active anticancer
compounds against pathologically distinct cancers.
Analysis of some hits displayed enhanced properties of
solubility and permeability and unusual structures that
could be further studied as potent lead compounds. This
research also indicates that in vitro analysis of different
cancers or resistant disease models or other phenotypic
assays with Meinox small molecule library could yield and
recognize novel potent compounds unique to the utilized
bioassay.
4. Discussion
Pharmaceutical modulation of small molecule diseases
follows a variety of common features that allow us to
foresee when a novel chemical agent with potent biological
activity could become a medicine in the future. One of
the underlying general characteristics of traded drugs
is their small molecular weight, but the production
of higher activity compounds is often correlated with
elevated molecular weights following the discovery of hits.
Compounds of larger weights, however, are less likely to
be absorbed and thus enter the area of influence. Thus,
the wish of a drug developer is to strive to keep molecular
weights as small as possible. Thus, the novel screening
library should follow these features as envisaged and

promote the further production of the drugs from the
onset of the identified hit compounds. To this end, Meinox
small molecule library contains 818 compounds (81.8%)
with a molecular weight less than 450.
A well-known measure of the hydrophilicity of the
compound is the logP value of a compound, which is the
logarithm of its partition coefficient between n-octanol
and water log. The weak absorption or permeation is
caused by low hydrophilicities and thus high logP values.
Compounds have been seen to have a fair tendency to be
well absorbed; ones logP value must not be greater than
5.0. To this end, the small molecule library of Meinox
established in this study has been examined for cLogP
values found to have 926 compounds (90.26%) of cLogP
values less than 5.
Aqueous solubility affects the absorption and
distribution properties of a compound greatly. A low
solubility is usually followed by slow absorption, meaning
that poorly soluble compounds are avoided generally in
drug discovery and development platforms. The logS value
estimation is based on mol/litre calculated solubility at base
10 of the logarithm. More than 80% of medications on the
market have a logS value higher than –4. In comparison,
Meinox small molecule library established in this study
contains 375 compounds (37.5%) with a value greater than
–4 and 641 compounds (64.1%) with a value greater than
–5 cLogS.
The polar surface area (PSA) is known as the surface
amount of all polar atoms (oxygen, nitrogen, sulfur and
phosphorus), including hydrogens that are also attached.
PSA is a widely used metric in medicinal chemistry for cell
permeability optimization. It is commonly thought that
molecules with a polar surface region of more than 140
square angstroms are bad at permeating cell membranes.
In addition, for molecules to cross the blood-brain barrier
and act on central nervous system receptors, PSA should
be less than 60 square angstroms. It seems that newly
established Meinox small molecule library in this study
includes 927 (92.7%) compounds with PSA values below
140, and 293 (29.3%) compounds with PSA values below
60.
Earlier estimates of possible toxicity may minimize
errors in the later stages of drug development due to
cytotoxicity, tumorigenicity, or reproductive issues.
The computational prediction methods are based on a
preset structural fragment that triggers toxicity warnings
if located in the current structure. Risk warnings by
computational analysis are by no means supposed to be a
predictor of toxicity that is entirely accurate. In the lack of
risk signs, it could not be inferred that a given product will
be absolutely free of any harmful effects. The prediction
process depends on the structural fragment which gives
rise to toxicity warnings should they be located in the

639

MAMMADOVA et al. / Turk J Biol
Soergel Distance

0.6
Cluster 1

B

Mx00711

Cluster 2

Cluster 3

Mx00796

Mx00519

Mx00623

Mx00201

Mx00745

Mx00710

Mx00581

Mx00102

Mx00691

Mx00771

Mx00715

Mx00737

Mx00794

Mx00711

0.0

0.2

0.4

Height

0.8

1.0

1.2

1.4

A

Cluster 4

Mx00794

Cluster 1
Mx00715

Mx00737

Mx00771

Cluster 2

Mx00102

Mx00581

Mx00691

Mx00710

Cluster 3

Mx00201

Mx00519

Mx00623

Mx00745

Mx00796

Cluster 4

Figure 8. Structural analysis of hits. A) Structural classification of common anticancer hits. B) Structures of identified anticancer
compounds from Meinox library of small molecules. Mx = Meinox compound ID.

RTECS database. We ran a number of toxic compounds
and a set of possibly nontoxic compounds through the
forecast to test the efficiency of the toxicity prediction in
the newly established Meinox small molecule library in
this study. The frequency of occurrence of any fragment
(core and fabricated fragments) within all compounds of
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that toxicity class such as mutagenicity, tumorigenicity,
reproductive or irritant effect was calculated by the
substructure search process. Based on the premise that
the drugs sold are essentially free from toxic effects, any
fragment was deemed a risk factor if it always existed as a
substructure of hazardous substances.
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Table. Druglikeness analysis of identified common anticancer compounds. Identified small molecules from Meinox library of
compounds were analyzed for their MW, cLogP, cLogS, Polar surface area, druglikeness, and predicted for mutagenicity, tumorigenicity,
reproductive effect, and irritation.

Mx00102

Total cLogP
MW* **
474.6 0.7341

cLogS Polar surface Druglikeness Mutagenicity Tumorigenic Reproductive
Irritant
***
area****
*****
prediction
prediction
effect prediction prediction
–2.603 93.8
10.497
None
None
None
None

Mx00201

336.8 2.7981

–4.147 52.83

–3.4385

None

None

None

None

Mx00519

373.5 3.7552

–6.194 99.94

–4.9099

High

Low

High

None

Mx00581

631.7 3.4038

–4.399 122.52

6.0525

None

None

None

None

Mx00623

251.3 3.3101

–3.822 42.35

–1.5828

None

None

None

None

Mx00691

421.5 0.461

–1.959 103.2

6.6593

None

None

None

None

Mx00710

349.4 2.6014

–4.478 77.15

1.0293

None

None

None

None

Mx00711

443.3 2.572

–4.583 97.62

–4.5155

None

None

Low

None

Mx00715

958.2 6.4181

–6.634 204.66

1.9808

None

None

None

None

Mx00737

285.2 –1.2693 –2.91

–2.2482

None

None

None

None

Mx00745

195.2 –0.0922 –2.203 121.41

2.2769

Low

None

None

None

Mx00771

219.3 –0.8458 –0.277 84.16

2.5386

None

None

None

None

Mx00794

442.3 3.5729

–5.378 84.73

–4.5155

None

None

Low

None

Mx00796

449.5 5.3826

–6.258 95.51

–2.2098

None

High

None

None

Meinox ID

139.54

*Good < 450, **Good < 5, ***Good > –4, ****Good < 60, ****Good > 0).

Meinox small molecule library allowed us to identified
both new (i.e. Mx00921, Mx00945) and previously
reported anticancer compounds (i.e. Mx00691, Mx00710,
Mx00737 and others). Intriguingly, several of the
identified common anticancer hits which reduced viability
of three cancers, pancreas, breast and blood cancer cell
lines, had previously reported or recently been approved
as antineoplastic agents through drug repurposing studies.
Mx00691, also known as Topotecan, has been used in the
treatment of colorectal, ovarian and nonsmall cell lung
cancer as antineoplastic agents (Noronha et al., 2020).
It is a derivative of camptothecin which binds to the
topoisomerase I-DNA complex. Mx00710, also known as
Panobinostat, is an antineoplastic and inhibitor of histone
deacetylase agent used with other agents of refractory or
relapsed myeloma (Mamdani and Jalal, 2020). It may also
contribute to G2/M phase cell cycle blockage and apoptosis.
Mx00737, also known as Fludarabine, is an antimetabolite
analog of vidarabine that poses antineoplasty (Barreca et
al., 2020). Mx00771, also known as Miglustat, is analogue
of D-glucose and used in the therapy of type 1 Gaucher
disease (Stirnemann et al., 2017). Intriguingly, to delay
the development of multiple myeloma, researchers have
recently repurposed the licensed drug miglustat (Ersek et
al., 2015). Mx00794, also known as (Gravina et al., 2014),
is a new agent that is being tested in a number of viral
indications as well as in inflammatory disorders as an oral
selective inhibitor of nuclear export (SINE). Additionally,

the prevention of canine tumors including lymphoma is
being investigated (Sadowski et al., 2018).
Different carcinomas might have different dependencies
of different molecular pathways. Therefore, while some
anticancer compounds are blocking the growth of a
particular cancer, it may not affect another type of cancer
cell line or carcinoma. This type of anticancer compounds
could be key in developing pathway/cancer specific
precision medicine approaches. Besides, some anticancer
compounds have broad activities; they block cancer cell
growth almost in every type of cancer that have been
treated. These compounds are usually cytotoxic to cells,
thus they may show cytotoxicity to healthy cells as well.
This limits use of these anticancer compounds in future
therapeutics if benefit to harm ratio is not good enough.
In brief, we have developed a library of small molecules
with theoretical and biologically active chemical entities.
The potent anticancer compounds were determined
for the PANC1, MCF7, and RS4-11 cell lines. The 1 μM
dose evaluation of the library revealed strong, unique or
highly active anticancer compounds for pathologically
distinct cancers. Hit analysis reveals higher solubility and
permeability and unique structures which can be further
analyzed as effective lead compounds. This research
also shows that in vitro analysis of different cancers or
disease-resistant models or other phenotypic assays with
the Meinox small molecule library could yield and define
novel potent compounds unique to the bioassay used.
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Figure S1. Small molecules in the Meinox small molecule library that inhibits PANC1 pancreatic adenocarcinoma growth at least
50% at 1 μM dose.

Figure S2. Small molecules in the Meinox small molecule library that inhibits MCF7 breast carcinoma growth at least 50% at 1
μM dose.
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Figure S3. Small molecules in the Meinox small molecule library that inhibits RS4-11 lymphoblastic leukemia growth at least 50%
at 1 μM dose.
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